X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The companies will employ GenEdit’s NanoGalaxy platform to discover and develop novel nanoparticles to deliver Genentech’s nucleic acid-based medicines for treatment of autoimmune disease.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $644.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration January 23, 2024
Details:
As part of the agreement, Sarepta obtains exclusive option rights to license polymer nanoparticles developed by GenEdit in the collaboration for up to four neuromuscular indications selected by Sarepta.
Lead Product(s): Genetic Medicine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2022
Details:
The funding will support the development of GenEdit’s NanoGalaxyTM platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.
Lead Product(s): Genetic Medicine Encapsulated Polymeric Nanoparticles
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
